An observational study in Chronic Arthritis, sponsored by University Hospital, Montpellier. Completed. Open to participants aged 3 Months and older. Per ClinicalTrials.gov, last updated 2016-09-21.
Sponsored by University Hospital, Montpellier · Observational
Use of genotyping for the optimization of treatment with biologics in chronic arthritis by looking for an association between certain alleles and response to treatment.
Chronic arthritis in children and in adults represent a public health problem in number and difficulty of treatment. 30% of patients are non-responders and / or relapse upon discontinuation of treatment. Some of these treatments are not always well tolerated, sometimes with infectious complications including tuberculosis limiting the use of biological therapies. This study will validate a battery of genetic markers to predict responders biotherapy, determine the prognosis of patients, these treatments are reserved for the most severe forms, and thus improve the care of patients.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's enrollment of 379 is above the median of 155 across 1,057 observational studies indexed under Arthritis.
Browse Arthritis studies →University Hospital, Montpellier is the lead sponsor of 1,244 studies on the registry; 225 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients referred for chronic arthritis
Exclusion Criteria:
Conservation at the end of the blood sample
Proportion of responsive patients with a given polymorphism (%)
Time frame: At the inclusion
Distribution of patients with a given biotherapy (%)
Time frame: At the inclusion
Distribution of patients presenting a given polymorphism (%)
Time frame: At the inclusion
No study locations are listed for this record.
Plan to share: No
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier